JP Morgan Maintains Overweight on Abbott Laboratories, Lowers Price Target to $118
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice TargetHot
JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $120 to $118.
JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $120 to $118.